Irving, TX, June 21, 2014 --(PR.com
)-- Choice Cancer Care has the Immunotherapy PD1 Inhibitor available for the treatment of cancer.
"At Choice Cancer Care, it has been always our goal to change the way patients live with cancer. The new PD-1 Inhibitor treatment is a Breakthrough Therapy for treating patients with advanced melanoma," said Dr. Gregory Echt, Founder of Choice Cancer Care.
The immune system naturally eliminates some cancers before they become life threatening. Researchers, therefore, thought that it should be possible to develop therapies that would train a patient’s immune system to destroy their cancer. Immunotherapy PD1 Inhibitor treatment is one such therapy. Such therapies, referred to as immunotherapies, are now beginning to revolutionize the treatment of some cancers, yielding both remarkable and durable responses.
Choice Cancer Care is committed to providing the best cancer treatments, with the goal of changing survival expectations and the way patients live with cancer.
For more information on the treatment using PD1 Inhibitor, call at 214.379.2700.
About Choice Cancer Care
Choice Cancer Care’s leadership philosophy is apparent in every interaction, every carefully made patient care plan, every phone call, every smile. It is not enough to be considered among the best providers in oncology treatment for a wide range of cancers. The specialists at Choice Cancer Care consider it to be an honor and privilege, and work hard each day to fulfill that promise to their patients, to their patient's families, to the community as a whole, and to themselves. Leadership is in each and every action at Choice Cancer Care.